SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mulanoon2007 who wrote (4064)12/21/2015 10:16:52 PM
From: jaybe1 Recommendation

Recommended By
civic08801

  Read Replies (1) of 4474
 
Although the authors open the door for pona after failure of any TKI, I think the current OPTIC trials (lower doses in 3L/4L and 2L after imatinib) capture the foreseeable potential for pona in R/R CP CML. Once generic imatinib reshapes the frontline market, the only question for 2L will be when to switch and which agent is the most efficacious and (relatively) tolerable. And IMO a nilo+ABL001 combo will not compete with pona on either count.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News